INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Inhibrx Biosciences, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$89.79−0.04 (-0.04%)

Close on Oct 19, 2026

Market cap: $1.41B
P/E (TTM): –
Dividend yield: –

Inhibrx Biosciences, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Cash & Equivalents	124	153	278	274	131	129	12	2.10
Cash & Short-Term Investments	124	153	278	274	131	129	12	2.10
Receivables	–	–	0.17	0.24	0.37	0.08	0.20	–
Prepaid Expenses & Other	8.44	7.38	17	6.37	6.93	2.89	3.58	–
Other Current Assets	0.24	0.38	0.37	0.18	0.59	0.69	0.38	–
Total Current Assets	133	160	295	280	139	132	16	–
Property, Plant & Equipment	3.73	6.20	6.42	2.50	3.15	3.49	3.23	–
Gross Property, Plant & Equipment	15	15	13	8.04	7.56	6.86	5.61	–
Accumulated Depreciation	-11	-8.89	-6.69	-5.54	-4.41	-3.37	-2.38	–
Operating Lease Right-of-Use Assets	5.54	7.34	2.95	4.72	6.34	7.83	7.45	–
Other Long-Term Assets	4.38	6.83	3.16	3.16	1.85	0.25	0.25	–
Total Assets	146	181	308	291	150	144	26	–
Accounts Payable	5.94	9.25	11	8.33	9.13	13	3.12	–
Accrued Expenses	26	30	43	17	9.62	13	4.83	–
Short-Term Debt	–	–	–	–	–	–	0	–
Current Portion of Long-Term Debt	–	–	0	–	–	0	3.56	–
Current Debt	–	–	0	–	–	0	3.56	–
Current Portion of Leases	2.33	1.60	2.06	1.86	1.67	1.50	1.11	–
Deferred Revenue (Current)	–	–	0	0.17	2.03	3.08	7.94	–
Other Current Liabilities	–	–	–	–	–	0	0.02	–
Total Current Liabilities	34	41	56	28	22	31	21	–
Long-Term Debt	101	0	207	–	–	–	–	–
Long-Term Leases	4.13	6.45	1.11	3.17	5.03	6.71	6.70	–
Operating Lease Liabilities	6.45	8.05	3.17	5.03	6.71	8.21	7.80	–
Other Long-Term Liabilities	–	–	–	–	0	0.18	0	–
Total Liabilities	138	47	264	233	98	68	61	–
Total Debt	101	0	207	–	–	0	3.56	–
Preferred Stock	0	0	0	0	0	0	0	–
Common Stock	0.00	0.00	0.01	0.00	0.00	0.00	0.00	–
Additional Paid-In Capital	254	240	657	430	280	221	-24	–
Retained Earnings	-246	-106	-614	-372	-227	-145	-69	–
Shareholders' Equity	7.99	134	44	58	52	75	-94	–
Total Equity	7.99	134	44	58	52	75	-94	-58
Total Liabilities & Equity	146	181	308	291	150	144	26	–
Shares Outstanding(shares)	15	14	47	11	9.75	9.43	4.54	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -9831.6%
Net margin: -10629.3%
Return on equity, FY2025: -197.8%

Financial strength

Current ratio: 5.07
Debt to equity: -3.33
Debt to assets: 114.3%
Cash to current liabilities: 475.1%

Valuation

P/E ratio: –
Price to sales: 1082.25
Price to book: –
Dividend yield: –